Posts

Posted on

Nextech AR Solutions Corp. to Acquire Silicon Valley AI-Powered 3D Model Creation Company Threedy.ai Inc. for US$9,500,000

Nextech AR Solutions Corp. to Acquire Silicon Valley AI-Powered 3D Model Creation Company Threedy.ai Inc. for US$9,500,000

VANCOUVER, British Columbia–(BUSINESS WIRE)–Nextech AR Solutions Corp. (“Nextech”) (OTCQB: NEXCF) (NEO: NTAR) (FSE: N29) is pleased to announce that it has signed a binding letter of intent (the “LOI”) dated May 14, 2021 with Threedy.ai Inc. (“Threedy”) to acquire all outstanding shares of Threedy. Threedy is an artificial intelligence (“AI”) company based in Silicon Valley, California, backed by prominent venture capitalists (“VCs”) and angle investors. Founded in 2018, they have been building AI technologies for the 3D model creation of physical products at scale. They have an expansive list of clients, including Walmart, Wayfair, Kohl’s Pier 1 Imports, K-mart Australia, Lighting Plus New Zealand, and many more.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210518005416/en/

(Graphic: Business Wire)

(Graphic: Business Wire)

Threedy’s patent-pending technology leverages AI to enhance the building of quality 3D models from simple 2D photos at scale through an AI-powered assembly line.

Using Threedy’s proprietary AI and computer vision innovations, the production of 3D models can be scaled to 1,000s of 3D models per week. Threedy has built a truly disruptive end-to-end solution around its model creation technology for the augmented reality (“AR”) industry. Through a simple JavaScript tag integration, product photos are automatically onboarded, 3D models are created for each product through the power of AI and hosted on the Threedy’s cloud, and 3D visualizations are served to client properties using web AR/3D, all within a single integrated platform. Nextech envisions that this platform will become the self-service AR platform for all its AR solutions including, e-commerce, AR advertising, Genie in the Bottle Holograms, AR Portals, and more.

Nextech’s acquisitions strategy is focused on creating net new revenue opportunities that scale with the rapid global adoption of AR, and Threedy is perfectly positioned to capitalize on that by offering a better industry solution for 3D content creation. 3D digital inventories from every major retailer and manufacturer are growing rapidly but it is still too slow and costly for most, with the biggest bottleneck for the global adoption of AR being 3D model creation at scale. The need to make 3D digital replicas easy, fast, and cost-effectively is a global need that has not been met until now. With this transaction, Nextech and Threedy are here to bring AI technology to the forefront of the digital transformation economy and build the bridge between the 2D and 3D world of content creation.

Evan Gappelberg CEO of Nextech AR Solutions Corp.’s Comments:

“I have been patiently waiting for a company to come along that not only understands AI but also understands that AI is the key to cracking the code on scaling AR content creation. Nima and Max are two rare entrepreneurs who have figured it out and are gutsy and smart enough to not only build their disruptive technology but also bring it to market through the world’s largest retailers. With Threedy’s technology and Nextech’s global sales and marketing machine, our combined AI teams and our existing AR tech and resources as a public company, I’m convinced that we will quickly take a leadership position in the AR industry”.

Nima Sarshar CEO of Threedy.ai, Inc.’s Comments:

“eCommerce has lived in the same `flatland` for 25 years now, and we have been attempting to fit a world that is 3D into 2D flat screens. The future of digital commerce, however, is 3D. Customers- businesses and consumers alike- are increasingly demanding to see the products they are buying online in as much detail as possible to interact with them immersively and see them in the space they are intended for before committing to a purchase. To that end, our vision is to create a 3D digital replica of every commercial product in the world. We could not have found a better partner than Evan and Nextech to make that vision a reality. Combining our resources and technologies, we will take the AR industry by storm and bring AR to retailers and brands at scales never imagined before.”

About Threedy.ai, Inc. CEO – Nima Sarshar, Ph.D:

Former tenured Associate Professor of Software Engineering, turned serial entrepreneur, with more than 50 peer-reviewed scientific papers and patents. Author of “Network-aware source coding and communication” by Cambridge University Press.Co-founder and CTO of Haileo, an early visual search AI company, CTO of inPowered, a leading AI content marketing platform. Most recently, lead Machine Learning Scientist at Apple (AAPL)

About Threedy.ai, Inc. CTO – Max Hwang, MSc:

Software executive with over 25 years of experience in Silicon Valley with expertise in enterprise software system design and global team management. BA in Computer Science and Economics from UC Berkeley MSc in Management of System Software Development from Carnegie Mellon University. Serial entrepreneur and early employees in Interwoven (went public & acquired by HP), Recommind (Acquired by OpenText), Baynote (Acquired by Kibo Commerce). Most recently, the founder & CEO of Code Above Lab Inc., a Silicon Valley software consulting firm, with clients including Adobe, Cloudera, Teradata, and Navinfo.

The transaction will be an all-stock purchase (the “Transaction”) for payment upon closing of US$9,500,000 worth of common shares of Nextech (the “Nextech Shares”). The number of Nextech Shares issuable to the stockholders of Threedy.ai will be calculated by dividing the aggregate value of the common shares of Nextech on the stock exchange where the majority of trading volume occurs for the twenty trading days prior to the date of the announcement of the closing of the Transaction, subject to a floor price of US$2.00 per Nextech Share as well as the policies of the Canadian Securities Exchange (“CSE”) and the Neo Exchange Inc. (“NEO”). The Nextech Shares will be subject to certain voluntary resale restrictions.

On closing, which is expected to take 30 days, the Threedy team, including the founders, will join Nextech. Nima Sarshar (co-founder and CEO of Threedy) and Max Hwang (co-founder & CTO of Threedy) will provide executive services to Threedy and Nextech (as applicable).

The Transaction is subject to the acceptance of the CSE and the NEO, the approval of the shareholders of Threedy and Nextech (if required), and the completion of satisfactory due diligence by Nextech.

About Nextech AR

Nextech develops and operates augmented reality (“AR”) platforms that transports three-dimensional (“3D”) product visualizations, human holograms and 360° portals to its audiences altering e-commerce, digital advertising, hybrid virtual events (events held in a digital format blended with in-person attendance) and learning and training experiences.

Nextech focuses on developing AR solutions however most of the Company’s revenues are derived from three e-Commerce platforms: vacuumcleanermarket.com (“VCM”), infinitepetlife.com (“IPL”) and Trulyfesupplements.com (“TruLyfe”). VCM and product sales of residential vacuums, supplies and parts, and small home appliances sold on Amazon

To learn more, please follow us on Twitter, YouTube, Instagram, LinkedIn, and Facebook, or visit our website: https://www.Nextechar.com.

The CSE and the NEO have not reviewed and do not accept responsibility for the adequacy or accuracy of this release.

Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, “will be” or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward-looking statements regarding the completion of the transaction are subject to known and unknown risks, uncertainties and other factors. There can be no assurance that such statements will prove to be accurate, as future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Nextech will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.

On behalf of the Board of Nextech AR Solutions Corp.

Evan Gappelberg

CEO and Director

For further information, please contact:

[email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Online Retail Consumer Electronics Retail Technology Audio/Video Software Hardware

MEDIA:

Photo
Photo
(Graphic: Business Wire)
Logo
Logo
Posted on

Leading Independent Proxy Advisory Firm Recommends Dynacor Shareholders Vote for All Proposed Resolutions at the Upcoming Annual Meeting of Shareholders

MONTREAL, May 18, 2021 (GLOBE NEWSWIRE) — Dynacor Gold Mines Inc. (TSX: DNG/OTC: DNGDF) (Dynacor or the Corporation) is pleased to announce that Glass Lewis and Co., LLC, a leading independent proxy advisory firm that provides voting recommendations to institutional investors, has recommended that the Corporation’s shareholders vote FOR all of the director nominees and meeting resolutions at Dynacor’s annual meeting of shareholders (the “Meeting”) scheduled for June 17, 2021.

The Meeting will take place 1, Place Ville Marie, 40th Floor, Montréal, Québec H3B 4M4 and via live webcast at https://lavery.zoom.us/j/62888814122. The Corporation strongly encourages shareholders to vote by proxy in advance of the Meeting and not to attend in person. Shareholders may attend the Meeting via live webcast, where all shareholders, regardless of geographic location and equity ownership, will have an equal opportunity to participate and engage with the Corporation, as well as other shareholders.

YOUR VOTE IS IMPORTANT! – PLEASE VOTE TODAY

The Board of Directors recommends that shareholders vote FOR all of the proposed resolutions.

Please submit your vote well in advance of the proxy voting deadline at 10:00 a.m. (Eastern Daylight Time) on June 15, 2021.

How to vote

Your vote is important regardless of the number of shares you own

Voting for Beneficial Shareholders

  • INTERNET: Go to www.proxyvote.com and enter your 16-digit control number found on your voting instruction form to vote online.
  • TELEPHONE: Call the toll-free telephone number listed on your voting instruction form and enter your 16-digit control number found on your voting instruction form to vote by telephone.

Voting for Registered shareholders

  • INTERNET: Go to www.astvotemyproxy.com. Enter the 13-digit control number printed on the form of proxy and follow the instructions on screen to vote.
  • TELEPHONE: Call 1-888-489-7352 and follow the voting instructions. You will need the 13-digit control number printed on the form of proxy to vote.

Shareholder Questions and Assistance

Shareholders who have questions or require voting assistance may contact Dynacor’s shareholder communication advisor and proxy solicitation agent, Laurel Hill Advisory Group, by telephone at 1-877-452-7184 (toll-free in North America) or 1-416-304-0211 (collect call outside North America) or by email at [email protected].

ABOUT DYNACOR

Dynacor is a dividend-paying industrial gold ore processor headquartered in Montreal, Canada. The corporation is engaged in gold production through the processing of ore purchased from the ASM (artisanal and small-scale mining) industry. At present, Dynacor operates in Peru, where its management and processing teams have decades of experience working with ASM miners. It also owns a gold exploration property (Tumipampa) in the Apurimac department.

The corporation intends to expand its processing operations in other jurisdictions as well.

Dynacor produces environmental and socially responsible gold through its PX IMPACT® gold program. A growing number of supportive firms from the fine luxury jewelry, watchmakers and investment sectors pay a small premium to our customer and strategic partner for this PX IMPACT® gold. The premium provides direct investment to develop health and education projects for our artisanal and small-scale miner’s communities.

Dynacor is listed on the Toronto Stock Exchange (DNG) and the OTC in the United States under the symbol (DNGDF).

FORWARD-LOOKING INFORMATION

Certain statements in the preceding may constitute forward-looking statements, which involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Dynacor, or industry results, to be materially different from any future result, performance or achievement expressed or implied by such forward-looking statements. These statements reflect management’s current expectations regarding future events and operating performance as of the date of this news release.

Toronto Stock Exchange (TSX): DNG

OTC (United States): DNGDF

Shares Outstanding: 38,727,524

Website: http://www.dynacor.com
Twitter: http://twitter.com/DynacorGold

PDF available: http://ml.globenewswire.com/Resource/Download/bda364c0-c6be-4db4-a7cf-7c1835789b6c 



CONTACT: For more information, please contact:

Director, Shareholder Relations
Dale Nejmeldeen
Dynacor Gold Mines Inc.
T: 514-393-9000 #230
E: [email protected]

Posted on

EVgo Announces Nomination of Utility and Energy Veteran Patricia K. Collawn to Join its Post-Merger Public Company Board of Directors

EVgo Announces Nomination of Utility and Energy Veteran Patricia K. Collawn to Join its Post-Merger Public Company Board of Directors

LOS ANGELES–(BUSINESS WIRE)–EVgo, (or the “Company”), the nation’s largest public fast charging network for electric vehicles (EVs) and the first powered by 100% renewable energy, today announced the nomination of Patricia K. Collawn to join its Board of Directors upon the closing of its previously announced business combination with Climate Change Crisis Real Impact I Acquisition Corporation (“CRIS”).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210518005345/en/

Patricia K. Collawn, nominated to join EVgo's post-merger public company board of directors (Photo: Business Wire)

Patricia K. Collawn, nominated to join EVgo’s post-merger public company board of directors (Photo: Business Wire)

Ms. Collawn is currently the Chairman and CEO of PNM Resources, and brings more than 25 years of operational, executive and board level leadership experience in the utility and energy sectors, including a record of success leading the advancement of the energy transition.

“Pat is a proven leader with world-class electric power and energy infrastructure experience. Pat shares EVgo’s passion for sustainability, and has been a pioneer in the charge toward decarbonization, making her specially qualified to serve on EVgo’s Board,” said David Nanus, EVgo Chairman and Co-Head of Private Equity at LS Power, the owner of EVgo. “As a board, we remain committed to performing at the highest level to support and elevate EVgo’s important work, and I look forward to partnering with Pat and the rest of the EVgo board as the Company executes its growth strategy and extends its leadership position in DC fast charging.”

“The EV revolution is underway, and convenient public fast charging remains essential in enabling EV adoption and a better driver experience,” said Cathy Zoi, CEO of EVgo. “With this incredible growth opportunity ahead of us, it is critical that we continue to surround EVgo’s world-class leadership and operational team with best-in-class executive advisory, and I look forward to serving alongside veterans like Pat to help chart EVgo’s future.”

EVgo previously announced the nomination of former Transportation Secretary Rodney Slater and Google Sustainability Officer Kate Brandt to its post-merger Board of Directors. To date, CRIS’s Board of Directors has nominated each of Elizabeth Comstock, Cathy Zoi, David Nanus, Joseph Esteves, Darpan Kapadia, John King, Kate Brandt, and Rodney Slater to serve as directors of the post-merger public company.

More on Patricia K. Collawn

Ms. Collawn currently serves as Chairman, President and Chief Executive Officer of PNM Resources, Inc., a publicly traded multi-state utilities corporation serving electricity customers. Under her leadership, PNM became the first U.S. investor-owned utility to set the goal of 100% carbon-free generation by 2040. Prior to that, Ms. Collawn was President and Chief Executive Officer of Public Service Company of Colorado, a subsidiary of Xcel Energy, Inc., where she managed a 6,500-person operation responsible for electric and gas distribution and transmission for more than 4 million customers.

Ms. Collawn also currently serves as a director of Equitrans Midstream Corporation (NYSE: ETRN), a midstream energy services company. Additionally, Ms. Collawn serves as Director of Edison Electric Institute (EEI), a national association of electric companies that develops programs to drive change in the electric power industry and communities they serve to deliver safe, reliable, affordable and cleaner energy; Electric Power Research Institute (EPRI), an independent, non-profit center for public interest energy and environmental research, including sustainability and carbon reduction matters for the electric industry; and Nuclear Electric Insurance Limited (NEIL), a mutual insurance company which insures all nuclear power plants in the United States as well as some facilities internationally.

Ms. Collawn currently serves as chairman of New Mexico Partnership, is former chairman of the Greater Albuquerque Chamber of Commerce, Kirtland Partnership Committee and of United Way of Central New Mexico. She is also a former member of the Economic Advisory Council for the Federal Reserve Bank of Kansas City.

Ms. Collawn earned her M.B.A. from Harvard Business School.

About EVgo

EVgois the nation’s largest public fast charging network for electric vehicles, and the first to be powered by 100% renewable energy. With more than 800 fast charging locations in 65 metropolitan areas across 34 states, EVgo owns and operates the most public fast charging locations in the US. and serves more than 250,000 customers. Founded in 2010, EVgo leads the way on transportation electrification, partnering with automakers; fleet and rideshare operators; retail hosts such as hotels, shopping centers, gas stations and parking lot operators; and other stakeholders to deploy advanced charging technology to expand network availability and make it easier for drivers across the U.S. to enjoy the benefits of driving an EV. As a charging technology first mover, EVgo works closely with business and government leaders to accelerate the ubiquitous adoption of EVs by providing a reliable and convenient charging experience close to where drivers live, work and play, whether for a daily commute or a commercial fleet. EVgo’s parent company is LS Power, a New York-headquartered development, investment and operating company focused on leading edge solutions for the North American power and energy infrastructure sector. For more information visit evgo.com and lspower.com.

About LS Power

LS Power is a development, investment and operating company focused on the North American power and energy infrastructure sector. Since its inception in 1990, LS Power has developed, constructed, managed or acquired more than 45,000 MW of power generation, including utility-scale solar, wind, hydro, natural gas-fired and battery energy storage projects, and has developed more than 660 miles of high voltage electric transmission. Additionally, LS Power actively invests in businesses focused on renewable energy and renewable fuels, as well as distributed energy resource platforms, such as CPower Energy Management, Endurant Energy and EVgo. Across its efforts, LS Power has raised in excess of $47 billion in debt and equity capital to support North American infrastructure. For more information, please visit www.lspower.com.

About CRIS

CRIS is a special-purpose acquisition company (SPAC) formed to identify and acquire a scalable company making significant contributions to the fight against the climate crisis. CRIS is co-sponsored by private funds affiliated with Pacific Investment Management Company LLC (PIMCO), which has more than $640 billion in sustainability investments across its portfolios. CRIS is led by a seasoned operations and leadership team that has decades of experience at the intersection of climate change and capitalism, and includes veterans from NRG, Credit Suisse, General Electric and Green Mountain Power. For more information, please visit www.climaterealimpactsolutions.com.

Important Information About the Business Combination and Where to Find It

In connection with the proposed business combination, CRIS (i) filed an amended preliminary proxy statement on May 17, 2021 and (ii) expects to file a definitive proxy statement, in each case, with the Securities and Exchange Commission (“SEC”). The definitive proxy statement and other relevant documents will be sent or given to the stockholders of CRIS as of the record date established for voting on the proposed business combination and will contain important information about the proposed business combination and related matters. Stockholders of CRIS and other interested persons are advised to read the preliminary proxy statement and any amendments thereto and, once available, the definitive proxy statement, in connection with CRIS’s solicitation of proxies for the meeting of stockholders to be held to approve, among other things, the proposed business combination because the proxy statement will contain important information about CRIS, EVgo and the proposed business combination. When available, the definitive proxy statement will be mailed to CRIS’s stockholders as of a record date to be established for voting on the proposed business combination. Stockholders will also be able to obtain copies of the proxy statement, without charge, once available, at the SEC’s website at www.sec.gov/ or by directing a request to: Climate Change Crisis Real Impact I Acquisition Corporation, 300 Carnegie Center, Suite 150 Princeton, NJ 08540, Attention: Secretary, telephone: (212) 847-0360. The information contained on, or that may be accessed through, the websites referenced in this press release is not incorporated by reference into, and is not a part of, this press release.

Participants in the Solicitation

CRIS, EVgo and their respective directors and executive officers may be deemed participants in the solicitation of proxies from CRIS’s stockholders in connection with the business combination. CRIS’s stockholders and other interested persons may obtain, without charge, more detailed information regarding the directors and officers of CRIS in CRIS’s amended preliminary proxy statement filed with the SEC on May 17, 2021 in connection with the proposed business combination. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies to CRIS’s stockholders in connection with the proposed business combination is set forth in the preliminary proxy statement for the proposed business combination. Additional information regarding the interests of participants in the solicitation of proxies in connection with the proposed business combination is also included in the preliminary proxy statement that CRIS has filed with the SEC.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. All statements, other than statements of present or historical fact included in this press release, regarding CRIS’s proposed business combination with EVgo, CRIS’s ability to consummate the transaction, the benefits of the transaction and the combined company’s future financial performance, as well as EVgo’s and the combined company’s strategy, future operations, estimated financial position, estimated revenues and losses, projected costs, prospects, plans and objectives of management are forward-looking statements. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the respective management of CRIS and EVgo and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of CRIS or EVgo. Potential risks and uncertainties that could cause the actual results to differ materially from those expressed or implied by forward-looking statements include, but are not limited to, changes in domestic and foreign business, market, financial, political and legal conditions; the inability of the parties to successfully or timely consummate the business combination, including the risk that any regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the combined company or the expected benefits of the business combination or that the approval of the stockholders of CRIS or EVgo is not obtained; failure to realize the anticipated benefits of business combination; risk relating to the uncertainty of the projected financial information with respect to EVgo; the amount of redemption requests made by CRIS’s stockholders; the overall level of consumer demand for EVgo’s products; general economic conditions and other factors affecting consumer confidence, preferences, and behavior; disruption and volatility in the global currency, capital, and credit markets; the financial strength of EVgo’s customers; EVgo’s ability to implement its business strategy; changes in governmental regulation, EVgo’s exposure to litigation claims and other loss contingencies; disruptions and other impacts to EVgo’s business, as a result of the COVID-19 pandemic and government actions and restrictive measures implemented in response; stability of EVgo’s suppliers, as well as consumer demand for its products, in light of disease epidemics and health-related concerns such as the COVID-19 pandemic; the impact that global climate change trends may have on EVgo and its suppliers and customers; EVgo’s ability to protect patents, trademarks and other intellectual property rights; any breaches of, or interruptions in, CRIS’s information systems; fluctuations in the price, availability and quality of electricity and other raw materials and contracted products as well as foreign currency fluctuations; changes in tax laws and liabilities, tariffs, legal, regulatory, political and economic risks. More information on potential factors that could affect CRIS’s or EVgo’s financial results is included from time to time in CRIS’s public reports filed with the SEC, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K as well as the preliminary and the definitive proxy statements that CRIS has filed or intends to file with the SEC in connection with CRIS’s solicitation of proxies for the meeting of stockholders to be held to approve, among other things, the proposed business combination. If any of these risks materialize or CRIS’s or EVgo’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that neither CRIS nor EVgo presently know, or that CRIS and EVgo currently believe are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect CRIS’s and EVgo’s expectations, plans or forecasts of future events and views as of the date of this press release. CRIS and EVgo anticipate that subsequent events and developments will cause their assessments to change. However, while CRIS and EVgo may elect to update these forward-looking statements at some point in the future, CRIS and EVgo specifically disclaim any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing CRIS’s or EVgo’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

EVgo

For Investors:

[email protected]

For Media:

[email protected]

LS Power

Steven Arabia

Director, Government Affairs & Media Relations

[email protected]

Climate Real Impact Solutions

For Investors:

Daniel Gross

[email protected]

For Media:

Isaac Steinmetz

Director of Media Relations

[email protected]

646-883-3655

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: General Automotive Automotive Alternative Vehicles/Fuels

MEDIA:

Logo
Logo
Photo
Photo
Patricia K. Collawn, nominated to join EVgo’s post-merger public company board of directors (Photo: Business Wire)
Posted on

Ocuphire Granted Two New U.S. Patents Covering Late-Stage Drug Candidate Nyxol®, Including for the Treatment of Presbyopia

Newly Issued Claims Extend Patent Protection to Year 2039 for Nyxol

®

Combination Therapy for Presbyopia

Provides Broader Protection for Nyxol

®

Across Indications on Methods of Use as Daily Administration

FARMINGTON HILLS, Mich. , May 18, 2021 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, announced today that the United States Patent and Trademark Office (USPTO) has issued two patents covering the Company’s late-stage product candidate, Nyxol (phentolamine mesylate). Both patents are directed to categories of subject matter eligible for listing in the U.S. FDA Orange Book:   

  • Nyxol for Treatment of Presbyopia:  U.S. Patent No. 10,993,932 issued on May 4, 2021 with claims to methods of treating presbyopia using a combination of phentolamine mesylate and low-dose pilocarpine. The term of this patent is to year 2039.
  • Nyxol for Daily Administration:  U.S. Patent No. 11,000,509 issued on May 11, 2021 with claims to methods of improving visual performance by daily administration of phentolamine mesylate at or near bedtime of the patient alone or in combination with one or more additional therapeutic agents. The term of the patent is to year 2034.

“We are quite pleased to announce the issuance of these two new U.S. patents that further strengthen our already robust patent portfolio for Nyxol,” said Mina Sooch, MBA, President and CEO of Ocuphire Pharma. “As we continue to meet milestones in our ongoing clinical trials investigating Nyxol for various refractive indications, patents like these provide the protection necessary to ensure commercial success. Importantly, Ocuphire owns all of the worldwide rights to Nyxol for all indications. These broader and new claims for daily use and presbyopia respectively reflect several years of strategic effort by our team and our patent counsel Dechert LLP. The timing is ideal with our recent announcement of enrollment completion in the VEGA-1 Phase 2 presbyopia trial and the upcoming expected top-line results by the end of June.”


Nyxol® Eye Drops Patent Estate

Ocuphire’s patent estate for Nyxol includes patents and patent applications for phentolamine mesylate formulations and methods of using phentolamine mesylate. Patent expiry on issued patents in the U.S. and globally are at least through 2034. As of May 17, 2021, Ocuphire’s patent estate relating to Nyxol contains seven issued U.S. patents, five pending U.S. non-provisional patent applications, one pending U.S. provisional patent application, as well as issued patents in Australia, Europe, Japan, and Mexico and pending patent applications in Australia, Canada, Japan, and other foreign countries. Ocuphire owns all of the worldwide rights to Nyxol for all indications.


About Ocuphire Pharma

Ocuphire is a publicly traded (NASDAQ: OCUP), clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire’s pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications. The company’s lead product candidate, Nyxol® (0.75% phentolamine ophthalmic solution) Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, and is being developed for several indications, including dim light or night vision disturbances (NVD), reversal of pharmacologically-induced mydriasis (RM), and presbyopia, and has been studied in 8 clinical trials including the recently completed Phase 3 trial in RM. Ocuphire reported positive topline data in March 2021 for MIRA-2, a Phase 3 FDA registration study for treatment of RM. Nyxol is also currently in Phase 3 clinical development for NVD and in Phase 2 for presbyopia. Ocuphire’s second product candidate, APX3330, is an oral tablet designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy (DR) and diabetic macular edema (DME) and has been studied in 11 Phase 1 and 2 trials. APX3330 is currently enrolling subjects in a Phase 2 clinical trial in subjects with DR/DME. As part of its strategy, Ocuphire will continue to explore opportunities to acquire additional ophthalmic assets and to seek strategic partners for late-stage development, regulatory preparation, and commercialization of drugs in key global markets. Please visit www.clinicaltrials.gov to learn more about Ocuphire’s completed Phase 2 trials, recently completed Phase 3 registration trial (NCT04620213), ongoing Phase 3 registration trial (NCT04638660), Phase 2 trial in presbyopia (NCT04675151), and Phase 2 trial in DR/DME (NCT04692688). For more information, please visit www.ocuphire.com. 


Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements concerning Ocuphire’s product candidates, results of ongoing and future clinical trials, and commercialization and market opportunities. These forward-looking statements are based upon Ocuphire’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: (i) the success and timing of regulatory submissions and pre-clinical and clinical trials, including enrollment and data readouts; (ii) regulatory requirements or developments; (iii) changes to clinical trial designs and regulatory pathways; (iv) changes in capital resource requirements; (v) risks related to the inability of Ocuphire to obtain sufficient additional capital to continue to advance its product candidates and its preclinical programs; (vi) legislative, regulatory, political and economic developments, (vii) changes in market opportunities, (viii) the effects of COVID-19 on clinical programs and business operations, (ix) the success and timing of commercialization of any of Ocuphire’s product candidates and (x) the maintenance of Ocuphire’s intellectual property rights. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors detailed in documents that have been and may be filed by Ocuphire from time to time with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Ocuphire undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.


Ocuphire Contacts

Mina Sooch, President & CEO  
Ocuphire Pharma, Inc.  
[email protected]  
www.ocuphire.com   

Corey Davis, Ph.D. 
LifeSci Advisors 
[email protected] 



Posted on

DunAn Microstaq offers an electronic expansion valve with autonomous superheat control as a retrofit kit for residential and commercial HVAC markets

AUSTIN, Texas, May 18, 2021 (GLOBE NEWSWIRE) — DunAn Microstaq, Inc. (DMQ), a MEMS technology company that innovates flow control solutions primarily for the HVAC, refrigeration and automotive industries, offers electronic expansion valve and superheat controller retrofit kits to support all residential and commercial HVAC systems with cooling capacities that can range from 1 ton to 300 tons.

The retrofit kit consists of the fastest responding electronic expansion valve in the industry, an autonomous superheat controller, a simple wiring harness and a 24VDC power supply. The retrofit kit for 1 – 8 tons (MSEV USHX kit) was the Gold award winner in the Refrigeration & Ice Machines category at 2015 Dealer Design Awards. The 10 – 25 tons retrofit kit (HC-MSEV USHX kit) was the Gold award winner in the HVAC Light Commercial Equipment category at 2018 Dealer Design Awards. DMQ now offers 26 – 50 tons retrofit kit (VHC-MSEV USHX kit) to support large commercial HVAC systems.

With low installation costs, low operational and maintenance costs, high energy savings and quick return on investment (ROI), the retrofit kit is very attractive for Energy Services Companies (ESCO) looking to augment their product offerings in the HVAC tune-up business. Existing commercial HVAC systems (7-10 years age) can benefit by converting mechanical expansion valves to DMQ’s EEV with autonomous valve control retrofit kit.      

The retrofit kit can be integrated with the DMQ’s intelligent HVAC-R cloud solution. The cloud solution that tracks the performance of the HVAC-R system in the field and can be easily monitored via mobile platform. System alarms and notifications when abnormal performance or trends are observed can be utilized for targeted preventive maintenance that can lead to better overall system performance.

About DunAn Microstaq

DunAn Microstaq, Inc. (DMQ) is a MEMS technology company dedicated to advancing flow control solutions primarily for the HVAC, refrigeration and automotive industries. Their pioneering work in microelectromechanical systems technology, understanding of customers’ needs and experiences translate into benefits that go far beyond flow control. DMQ solutions accelerate product development cycles, cut across design challenges, create warehousing efficiencies and reduce deployment time. With a core technology so versatile, DMQ can package its devices along with the sensing and controls software for custom applications to fit a multitude of markets. For more information about DMQ products, email [email protected] or visit www.dmq-us.com

Media Contact: 

Dhaman Besarla
Systems & Applications Engineering Manager
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a43f0cb9-64d8-477e-ac70-9871ca691cc7



Posted on

Revolution Medicines to Participate in Cowen 2nd Annual Virtual Oncology Innovation Summit

REDWOOD CITY, Calif., May 18, 2021 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that the company will participate in the upcoming Cowen 2nd Annual Virtual Oncology Innovation Summit. Steve Kelsey, M.D., president, research and development, will be the featured speaker in a fireside chat at the event.

Details of the company’s participation are as follows:

  • Cowen 2

    nd

    Annual Virtual Oncology Innovation Summit

    Conference Date: May 20-21, 2021
    Fireside Chat Time/Date: 12:40 p.m. Eastern on Friday, May 21, 2021
    Format: Virtual conference

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites.

The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. RAS(ON) Inhibitors in development include RMC-6291, RMC-6236, and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in development include RMC-4630, RMC-5552, and RMC-5845.



Contacts:

For Investors:
Vida Strategic Partners
Stephanie Diaz
415-675-7401
[email protected]

For Media:
Vida Strategic Partners
Tim Brons
415-675-7402
[email protected]

Posted on

Stoke Therapeutics to Present at the UBS Global Healthcare Virtual Conference

Stoke Therapeutics to Present at the UBS Global Healthcare Virtual Conference

BEDFORD, Mass.–(BUSINESS WIRE)–Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at the UBS Global Healthcare Virtual Conference on Monday, May 24, 2021, at 5:00 p.m. ET.

A live audio webcast of the presentation, which will be conducted in fireside chat format, will be available on the Investors & Media section of Stoke’s website at https://investor.stoketherapeutics.com/. A replay of the webcast will be available for 30 days following the fireside chat.

About Stoke Therapeutics

Stoke Therapeutics (Nasdaq: STOK) is a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines. Using the Company’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. The Company’s first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~50% of normal protein levels leads to disease. The Company is pursuing treatment for a second haploinsufficient disease, autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Stoke’s initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting the Company’s belief in the broad potential for its proprietary approach. Stoke is headquartered in Bedford, Massachusetts, with offices in Cambridge, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ or follow the Company on Twitter at @StokeTx.

Stoke Investor Contact:

Eric Rojas

Vice President, Investor Relations

[email protected]

617-312-2754

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Health Genetics Other Health General Health Pharmaceutical Optical Biotechnology

MEDIA:

Logo
Logo
Posted on

SL Green Announces Sale of 635-641 Sixth Avenue

Values Midtown South Property Over $1,200 per square foot

NEW YORK, May 18, 2021 (GLOBE NEWSWIRE) — SL Green Realty Corp. (NYSE:SLG), Manhattan’s largest office landlord, today announced the sale of 635-641 Sixth Avenue for a gross sales price of $325.0 million. The property is comprised of two adjoined buildings totaling 8 stories and 267,000 square feet, occupying the full western block-front on Sixth Avenue from 19th Street to 20th Street in Midtown South. The transaction is expected to close in the second quarter of 2021, subject to customary closing conditions, and generate net cash proceeds to SL Green of approximately $312.5 million.

“New York City’s revitalization continues as does the demand for Class A office buildings,” said Harrison Sitomer, Senior Vice President. “The disposition at a sale price of more than $1,200 per square foot is a result of extensive repositioning and leasing efforts at the property, which is further evidence of the breadth of expertise that the SL Green platform brings to the table. Completion of this transaction represents another step in the successful execution of our 2021 business plan.”

The property is currently 94% leased and anchored by multi-national enterprise software company, Infor, through 2030, following a recently executed renewal and extension. SL Green acquired the Property in 2012 for $173.0 million and completed its redevelopment in 2015, including a new lobby, elevators, state-of-the-art building systems and a one-of-a-kind penthouse rooftop that includes outdoor amenity and event space.

Darcy Stacom, William Shanahan and Doug Middleton of CBRE represented SL Green in the transaction.

About SL Green Realty Corp.

SL Green Realty Corp., Manhattan’s largest office landlord, is a fully integrated real estate investment trust, or REIT, that is focused primarily on acquiring, managing and maximizing value of Manhattan commercial properties. As of March 31, 2021, SL Green held interests in 84 buildings totaling 37.8 million square feet. This included ownership interests in 28.3 million square feet of Manhattan buildings and 8.7 million square feet securing debt and preferred equity investments.

Forward Looking Statement

This press release includes certain statements that may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and are intended to be covered by the safe harbor provisions thereof. All statements, other than statements of historical facts, included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future, are forward-looking statements. Forward-looking statements are not guarantees of future performance and actual results or developments may differ materially, and we caution you not to place undue reliance on such statements. Forward-looking statements are generally identifiable by the use of the words “may,” “will,” “should,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “project,” “continue,” or the negative of these words, or other similar words or terms.

Forward-looking statements contained in this press release are subject to a number of risks and uncertainties, many of which are beyond our control, that may cause our actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by forward-looking statements made by us. Factors and risks to our business that could cause actual results to differ from those contained in the forward-looking statements include risks and uncertainties related to the on-going COVID-19 pandemic and the duration and impact it will have on our business and the industry as a whole and the other risks and uncertainties described in our filings with the Securities and Exchange Commission. Except to the extent required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of future events, new information or otherwise.

SLG – A&D

Matt DiLiberto
Chief Financial Officer
212.594.2700

 



Posted on

Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call Tuesday May 25, 2021 at 4:30 PM ET

Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call Tuesday May 25, 2021 at 4:30 PM ET

BROOKLYN, N.Y.–(BUSINESS WIRE)–Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company currently focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders and monogenic diseases, today announced that management will host a conference call on Tuesday, May 25, 2021 at 4:30 p.m. Eastern Time (ET).

Participants are asked to pre-register for the call through the following link: http://www.directeventreg.com/registration/event/6819283. Please note that registered participants will receive their dial in number upon registration and will dial directly into the call.

The conference call will also be available through a live webcast found here.

The Company invites participants to pre-submit questions to [email protected] until 5:00 p.m. Eastern Time (ET) on May 20, 2021 (live questions will not be accepted during the call). Please use the subject line, “BTX Call Questions” for this correspondence. The Company will do its best to address all pre-submitted questions at the conclusion of prepared remarks.

About Brooklyn ImmunoTherapeutics

Brooklyn is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. The company is also expoloring opportunities to advance oncology, blood disorders, and monogenic disease therapies using leading edge gene editing/cell therapy technology through the newly acquired license from Factor Bioscience Limited and Novellus Therapeutics Limited.

Brooklyn’s most advanced program is studying the safety and efficacy of IRX-2 in patients with head and neck cancer. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.

For more information about Brooklyn and its clinical programs, please visit www.BrooklynITx.com.

Investor Relations Contact:

CORE IR

516-222-2560

[email protected]

Media Contact:

MacDougall

Nicholas Chang

[email protected]

781-235-3060

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health

MEDIA:

Logo
Logo
Posted on

Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody Program

Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody Program

Agenus to receive a $200 million upfront payment and up to $1.36 billion in milestone payments

NEW YORK & LEXINGTON, Mass.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) and Agenus Inc. (NASDAQ: AGEN) today announced that they have entered into a definitive agreement under which Bristol Myers Squibb will be granted a global exclusive license to Agenus’ proprietary bispecific antibody program, AGEN1777, that blocks TIGIT and a second undisclosed target. AGEN1777 is an Fc-enhanced antibody in late preclinical development designed to target major inhibitory receptors expressed on T and NK cells to improve anti-tumor activity. In preclinical studies this approach has shown significant potential in tumor models where anti-PD-1 or anti-TIGIT monospecific antibodies alone are ineffective.

Under the agreement, Bristol Myers Squibb will become solely responsible for the development and any subsequent commercialization of AGEN1777 and its related products worldwide. Agenus will receive a $200 million upfront payment and up to $1.36 billion in development, regulatory and commercial milestones in addition to tiered double-digit royalties on net product sales. Agenus will retain options to conduct clinical studies under the development plan, to conduct combination studies with certain other Agenus pipeline assets, and also, upon commercialization, to co-promote AGEN1777 in the US. The agreement is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

Agenus expects to file an Investigational New Drug (“IND”) application for the development of AGEN1777 with the U.S. Food and Drug Administration in the second quarter of 2021. Bristol Myers Squibb intends to advance the research and development of AGEN1777 in immuno-oncology (“I-O”) for high priority tumor indications including non-small cell lung cancer.

“AGEN1777’s differentiated mechanism of action provides the potential for potent anti-tumor activity; catalyzing our clinical TIGIT strategy aimed at serving more patients with unmet needs in cancer,” said Debbie Law, D.Phil., Senior Vice President, Head of Tumor Microenvironment Thematic Research Center, Bristol Myers Squibb. “We look forward to working with Agenus to develop this important therapy as we continue to combat I-O resistance.”

“We are pleased to partner with Bristol Myers Squibb to develop and commercialize AGEN1777. Their stellar record of success in this area has been an important determinant for our decision to enter into this transaction,” said Garo Armen, PhD, Chairman and Chief Executive Officer of Agenus. “Through such transactions we are able to balance between advancing our portfolio with highly qualified collaborators, while retaining our other innovations for speedy development and commercialization by Agenus.”

About AGEN1777

AGEN1777 is a potentially first-in-class bispecific anti-TIGIT antibody engineered with an enhanced Fc region for high binding affinity and improved T and NK cell activation.

About Agenus

Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body’s immune system to fight cancer. The Company’s vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.

Agenus Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding clinical development and regulatory plans and timelines related to AGEN1777 and other programs, potential receipt of development, regulatory and commercial milestones and the potential clinical benefit of such programs. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram.

Bristol Myers Squibb Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products and the license agreement. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on historical performance and current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include, among others, that the expected benefits of, and opportunities related to, the license agreement may not be realized by Bristol Myers Squibb or may take longer to realize than anticipated and that Bristol Myers Squibb may fail to discover and develop any commercially successful product candidates through the license agreement. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb’s business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2020, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.

corporatefinancial-news

Bristol Myers Squibb

Media:

[email protected]

Investors:

Tim Power, 609-252-7509, [email protected]

Nina Goworek, 908-673-9711, [email protected]

Agenus

Media:

Kimberly Ha, KKH Advisors, 917-291-5744, [email protected]

Investors:

Jan Medina, CFA, Agenus, 781-674-4490, [email protected]

KEYWORDS: New York Massachusetts United States North America

INDUSTRY KEYWORDS: Biotechnology General Health Pharmaceutical Health

MEDIA:

Logo
Logo